Last reviewed · How we verify
Placebo in addition to UDCA therapy
Placebo in addition to UDCA therapy is a Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Primary biliary cholangitis.
Placebo does not have a known mechanism of action.
Placebo does not have a known mechanism of action. Used for Primary biliary cholangitis.
At a glance
| Generic name | Placebo in addition to UDCA therapy |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Gastrointestinal |
| Phase | Phase 3 |
Mechanism of action
As a placebo, it does not contain any active pharmaceutical ingredient and therefore does not have a known mechanism of action. It is used as a control in clinical trials to compare the efficacy of active treatments.
Approved indications
- Primary biliary cholangitis
Common side effects
- Injection site reaction
- Fatigue
- Nausea
Key clinical trials
- Fecal Microbiota Transplantation for Primary Sclerosing Cholangitis - Randomized Study Versus Sham Transplantation (PHASE2)
- Integrative Liver-Targeted Therapy for Diabetic Macular Edema: Combining Tauroursodeoxycholate and Traditional Chinese Medicine. (PHASE2)
- Study of Saroglitazar Magnesium for PBC Patients With Incomplete Response or Intolerant to UDCA Therapy (PHASE3)
- Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC (PHASE2)
- Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. (PHASE2)
- Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy (PHASE3)
- Ursodeoxycholic Acid (UDCA) as a Neuroprotective Adjuvant Treatment to Rhegmatogenous Retinal Detachment Surgery (PHASE3)
- S-adenosylmethionine (SAMe) in Patients With Primary Sclerosing Cholangitis (PSC) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo in addition to UDCA therapy CI brief — competitive landscape report
- Placebo in addition to UDCA therapy updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI
Frequently asked questions about Placebo in addition to UDCA therapy
What is Placebo in addition to UDCA therapy?
How does Placebo in addition to UDCA therapy work?
What is Placebo in addition to UDCA therapy used for?
Who makes Placebo in addition to UDCA therapy?
What development phase is Placebo in addition to UDCA therapy in?
What are the side effects of Placebo in addition to UDCA therapy?
Related
- Manufacturer: Assistance Publique - Hôpitaux de Paris — full pipeline
- Therapeutic area: All drugs in Gastrointestinal
- Indication: Drugs for Primary biliary cholangitis
- Compare: Placebo in addition to UDCA therapy vs similar drugs
- Pricing: Placebo in addition to UDCA therapy cost, discount & access